Clinical Trial Update: Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Combination of trastuzumab with NK immunotherapy studied in recurrent breast cancer across Phase 1 and Phase 2; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• NK immunotherapy (natural killer cell-based immunotherapy)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Recurrent Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED